Odycell

Odycell is transforming cancer treatment by combining cell therapy with nanotechnology to overcome the limitations of current CAR-T approaches, particularly in solid tumors. While CAR-T therapies have shown curative potential in blood cancers, they fail in nearly 90% of cancer cases—solid tumors—primarily due to the hostile tumor microenvironment, which limits immune cell infiltration, persistence, and function. At the same time, complex and costly viral manufacturing makes these therapies inaccessible to most patients. Odycell is developing a non-viral nanotechnology platform that reprograms a patient’s immune cells at 90% lower cost and 80% faster than conventional CAR-T manufacturing. Our platform is based on a dual-nanoparticle system: Nuclear Nanoparticles (NuNPs) and Killer Nanoparticles (KNPs). NuNPs deliver genetic material directly into the cell nucleus without the use of viral vectors, while KNPs act within the tumor microenvironment to disrupt immunosuppressive barriers, enabling immune cells to remain active and effective. By addressing both manufacturing bottlenecks and tumor-driven immunosuppression, Odycell’s platform reduces cost and time, prevents immune cell exhaustion, and unlocks the potential of cell therapies as first-line treatments for solid tumors.